Home Cart Sign in  
Chemical Structure| 1001264-89-6 Chemical Structure| 1001264-89-6
Chemical Structure| 1001264-89-6

*Storage: Keep in dark place,Sealed in dry,Store in freezer, under -20°C.

Ipatasertib

CAS No.: 1001264-89-6

Ipatasertib (GDC-0068) is an orally active, highly selective, and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, and 8 nM for Akt1/2/3, respectively. It synchronously activates FoxO3a and NF-κB through Akt inhibition, leading to p53-independent activation of PUMA. Ipatasertib induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models.

Synonyms: GDC-0068;RG7440

4.5 *For Research Use Only !

Cat. No.: A115731 Purity: 98%

Change View

Size Price

USA Stock *0-1 Day

Global Stock *5-7 Days

In Stock
5mg łÿó¶ÊÊ In Stock In Stock Login
10mg łó§¶ÊÊ Inquiry In Stock Login
25mg łÇîó¶ÊÊ In Stock In Stock Login
50mg ł§ÿò¶ÊÊ In Stock In Stock Login
100mg łďÊî¶ÊÊ In Stock In Stock Login
250mg łÇÍÇî¶ÊÊ In Stock In Stock Login

Please Login or Create an Account to: See VIP prices and availability

  • 5mg

    łÿó¶ÊÊ

  • 10mg

    łó§¶ÊÊ

  • 25mg

    łÇîó¶ÊÊ

  • 50mg

    ł§ÿò¶ÊÊ

  • 100mg

    łďÊî¶ÊÊ

  • 250mg

    łÇÍÇî¶ÊÊ

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Product Details of [ Ipatasertib ]

CAS No. :1001264-89-6
Formula : C24H32ClN5O2
M.W : 458.00
SMILES Code : O=C(N1CCN(C2=C([C@H](C)C[C@H]3O)C3=NC=N2)CC1)[C@@H](C4=CC=C(Cl)C=C4)CNC(C)C
Synonyms :
GDC-0068;RG7440
MDL No. :MFCD22124514
InChI Key :GRZXWCHAXNAUHY-NSISKUIASA-N
Pubchem ID :24788740

Safety of [ Ipatasertib ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of [ Ipatasertib ]

PI3K-AKT

ALK Isoform Comparison

Name Akt Akt1 Akt2 Akt3 Purity
Honokiol 98%
PF-04691502 ++++

P-Akt (T308), IC50: 7.5 nM

P-Akt (S473), IC50: 3.8 nM

98+%
PHT-427 +

Akt, Ki: 2.7 μM

98%
Deguelin 98%
TIC10 isomer 98+%
Perifosine +

Akt, IC50: 4.7 μM

98%
Miltefosine 98%
Triciribine +

Akt, IC50: 130 nM

98%
A-674563 HCl +++

Akt1, Ki: 11 nM

99%
CCT128930 +++

Akt2, IC50: 6 nM

95%
Uprosertib +

Akt1, IC50: 180 nM

+

Akt2, IC50: 328 nM

++

Akt3, IC50: 38 nM

99%
Afuresertib ++++

Akt1, Ki: 0.08 nM

++++

Akt2, Ki: 2 nM

++++

Akt3, Ki: 2.6 nM

99%
Miransertib ++++

Akt1, IC50: 5 nM

++++

Akt2, IC50: 4.5 nM

++

Akt3, IC50: 16 nM

98+%
GSK-690693 ++++

Akt1, IC50: 2 nM

+++

Akt2, IC50: 13 nM

+++

Akt3, IC50: 9 nM

99%
AT7867 ++

Akt1, IC50: 32 nM

++

Akt2, IC50: 17 nM

++

Akt3, IC50: 47 nM

98+%
MK-2206 2HCl +++

Akt1, IC50: 8 nM

+++

Akt2, IC50: 12 nM

+

Akt3, IC50: 65 nM

98%
Ipatasertib ++++

Akt1, IC50: 5 nM

++

Akt2, IC50: 18 nM

+++

Akt3, IC50: 8 nM

98%
Capivasertib ++++

Akt1, IC50: 3 nM

+++

Akt2, IC50: 8 nM

+++

Akt3, IC50: 8 nM

98%

Biological Activity

Target
  • Akt3

    Akt3, IC50:8 nM

  • Akt1

    Akt1, IC50:5 nM

  • Akt2

    Akt2, IC50:18 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03341884 Hepatic Insufficiency PHASE1 COMPLETED 2018-06-26 Clinical Pharmacology of Miami... More >>, Inc., Miami, Florida, 33014, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, 37920, United States|American Research Corporation Inc., San Antonio, Texas, 78215, United States Less <<
NCT04467801 NSCLC Stage IV|NSCLC Stage III... More >>B Less << PHASE2 RECRUITING 2025-08-25 The University of Kansas Cance... More >>r Center (KUCC), Fairway, Kansas, 66205, United States|The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, 66205, United States|The University of Kansas Cancer Center, Overland Park Clinic, Overland Park, Kansas, 66210, United States|The University of Kansas Cancer Center, North Clinic, Kansas City, Missouri, 64154, United States|The University of Kansas Cancer Center, Lee's Summit Clinic, Lee's Summit, Missouri, 64064, United States Less <<
NCT04341259 Solid Tumors PHASE1 COMPLETED 2023-04-06 Fudan University Shanghai Canc... More >>er Center, Shanghai City, 200120, China Less <<
NCT01090960 Solid Cancers PHASE1 COMPLETED 2025-02-15 Barcelona, 08035, Spain|Valenc... More >>ia, 46010, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.18mL

0.44mL

0.22mL

10.92mL

2.18mL

1.09mL

21.83mL

4.37mL

2.18mL

References

 

Historical Records

Categories